The international surgical journal with global reach

Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trial. Cancer 2019; 125: 2185-2193

Published: 29th April 2020

Authors: Yu K-D, Wu S-Y, Liu G-Y, Wu J, Di G-H, Hu Z et al.

Conclusion

In this study that included 249 women, addition of endocrine treatment improved objective response rate from 72.6 to 84.8 per cent, P=0.02. The response was better in women whose tumours had a higher Ki-67 index.

Pubmed Link